Equities

Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)48.31
  • Today's Change2.22 / 4.82%
  • Shares traded626.89k
  • 1 Year change+6.36%
  • Beta0.8042
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments257176137
Total Receivables, Net1158979
Total Inventory10610493
Prepaid expenses9.067.567.27
Other current assets, total2.442.442.44
Total current assets490378318
Property, plant & equipment, net316265271
Goodwill, net3.223.133.31
Intangibles, net6103436
Long term investments152.413.99
Note receivable - long term------
Other long term assets262117
Total assets1,513742672
LIABILITIES
Accounts payable252122
Accrued expenses1986770
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.443.052.20
Other current liabilities, total1.614.579.08
Total current liabilities22595104
Total long term debt5907375
Total debt5907677
Deferred income tax--0.140.53
Minority interest----0
Other liabilities, total594547
Total liabilities873213226
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital486455422
Retained earnings (accumulated deficit)409272180
Treasury stock - common(247)(190)(150)
Unrealized gain (loss)------
Other equity, total(8.48)(8.62)(6.77)
Total equity639529446
Total liabilities & shareholders' equity1,513742672
Total common shares outstanding484848
Treasury shares - common primary issue1110.008.73
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.